nmdp logo

Severe aplastic anemia

Transplant advances and outcomes

Acquired aplastic anemia is thought to have an autoimmune component in many patients, and immunosuppressive therapy is a typical frontline therapy. Patients with aplastic anemia are classified based on the severity of their marrow aplasia. Those with severe aplastic anemia (SAA) are candidates for allogeneic hematopoietic cell transplantation (HCT). [1-4]

Recommended timing for transplant consultation

  • At diagnosis

References

  1. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017; 130(21): 2257-2264. Access
  2. Tolar J, Sodani P, Symons H. Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant. 2015; 50(5): 619-627. Access
  3. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012; 120(6): 1185-1196. Access
  4. Smith AR, Wagner JE. Current clinical management of Fanconi anemia. Expert Rev Hematol. 2012; 5(5): 513-522. Access